IRCT2017020210417N6
Completed
未知
Evaluation of Direct-Acting Antiviral Regimens Effectiveness in Achieving Undetectable Viral Load in Chronic Hepatitis C Patients in Iran
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kermanshah University of Medical Sciences
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Being diagnosed with hepatitis C and having a detectable viral count; Having not received any medications yet or being unresponsive to previous interferon\-based treatments; Providing a freely signed consent form to be treated with new generic medications.
- •Exclusion criteria :Having a renal failure defined as eGFR
- •\< 30 mL/min; Having a very advanced liver disease defined as MELD score \> 20 or Child\-Pugh score
- •\> 12; Heart rate \< 50 beats/min; History of previous treatment failure with sofosbuvir\-based regimen; History of taking amiodarone within the last 6 months; Not consenting to participate in the study.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Enrolling By Invitation
Not Applicable
Effectiveness and safety of direct acting antivirals for the management of patients with chronic hepatitis C virus in Thailand : A real-life multicenter study.1.End of treatment response (ETR) is the rate of treatment response. At the temple at the time of study discontinuance Which is divided into biochemical responses (with liver enzymes,ALT) and virologDAA.Chornic hepatitis C.TCTR20200313005one200
Recruiting
Not Applicable
Antiviral therapy with direct acting anti-virals in hepatitis C patients.Chronic hepatitis CJPRN-UMIN000016288Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine500
Completed
Phase 3
Comparative study in childrens with chronic Hepatitis B virus infection who are HBeAg positive.CTRI/2011/09/002001The pharmaceutical company sponsoring this study is BristolMyers Squibb180
Active, not recruiting
Phase 1
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-PositiveCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 12.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2009-016357-17-GRBristol-Myers Squibb International Corporation257
Active, not recruiting
Not Applicable
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infection. - NDHepatitis B VirusMedDRA version: 9.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2007-001269-14-ITBRISTOL-M.SQUIBB84